Ozempic alternatives: Could weight-loss injections soon become cheaper in South Africa?
South Africans could see greater competition and potentially lower prices in the weight-loss medication market following regulatory approval for a generic semaglutide pen developed by pharmaceutical manufacturer Aspen Pharmacare. The approval, granted in South Africa and Brazil for the treatment of type 2 diabetes in adults, could pave the way for another alternative to established weight-loss medications such as Ozempic. Speaking to CapeTalk's John Maytham, Bhekisisa Centre for Health Journalism founder and Editor-in-Chief Mia Malan explained that doctors can legally prescribe semaglutide for weight loss, even though the new generic has been registered for diabetes treatment. She said prescribing medication for a condition other than the one for which it is registered is known as off-label prescribing. In the case of semaglutide, this is already common practice. Related articles: — GLP-1 weight-loss drugs aren't a silver bullet for obesity, warns health expert — Generic weight loss drug on SA's shelves, says health writer — From Ozempic to generics: Will authorised weight-loss drugs become affordable? More competition could mean cheaper weight-loss injections Semaglutide is the active ingredient in Ozempic and is also found in generic alternatives such as Semagard. Aspen's entry into the market could increase competition, although Malan cautioned that the arrival of the first few generics does not necessarily translate into dramatically lower prices. Semagard, manufactured by an Indian company, is currently about 18% cheaper than Ozempic. Malan said prices were likely to decline further as more pharmaceutical companies received approval to manufacture generic versions of the medication. South Africa's medicines regulator, SAHPRA, has another 30 applications pending for generic semaglutide products. However, consumers should not necessarily expect substantial savings immediately. Malan said it could take another year or two for increased competition to have a more significant effect on prices. What do Ozempic and its alternatives cost in South Africa? For people considering weight-loss medication, the current monthly cost remains a significant barrier. Malan provided the following approximate prices for semaglutide products: — Ozempic: Approximately R1,550 a month for the lowest dosage, rising to as much as R3,000 for higher dosages. — Semagard: Approximately R1,265 a month for the lowest dosage. — Extensior: Around R150 cheaper than Ozempic. The product is manufactured by Novo Nordisk, the company behind Ozempic. While generic alternatives are already somewhat cheaper, the difference is not yet substantial. Malan said studies suggested semaglutide could potentially be manufactured for between R100 and R200 a month while still allowing companies to make a profit. However, she cautioned that this did not mean consumers would necessarily see prices drop to those levels. One possibility for improving affordability would be government procurement. If the state decided to purchase large quantities of the medication for patients, it could potentially negotiate significantly lower prices through large-scale tenders. Malan pointed to HIV treatment as an example of how government procurement can bring down medication costs. Not all weight-loss medications work in the same way Malan also explained that different weight-loss medications target different numbers of GLP-1 hormones, which can influence how quickly patients lose weight. Semaglutide targets one hormone, while tirzepatide, the active ingredient in Mounjaro, targets two. Retatrutide, which is still being tested in clinical studies and is not yet on the market, targets three hormones. Malan said studies generally showed a trend towards faster weight loss as more hormones were targeted. She explained that semaglutide generally produces slower weight loss than tirzepatide. Semaglutide's patent expired in South Africa in March 2026, opening the door for generic manufacturers. However, the patent for tirzepatide has not yet expired, meaning generic alternatives are not expected to enter the market just yet. Long-term treatment comes with important considerations While cheaper medication could make weight-loss treatment accessible to more South Africans, Malan warned that patients should understand the longer-term implications before starting treatment. She said weight-loss medication was generally intended for lifelong use, with studies showing that people could regain weight relatively quickly after stopping treatment. Malan also highlighted the potential loss of muscle alongside fat during treatment. She stressed that patients should receive appropriate guidance on exercise and building muscle when using these medications. The potential benefits of increased competition therefore extend beyond the price consumers pay each month. South Africa has particularly high obesity rates, and Malan said these medications could also have important implications for people living with HIV. She pointed to evidence showing that some people taking antiretroviral treatment, particularly Black women, experience significant weight gain after starting treatment. Greater access to affordable medication could therefore have implications for a much wider group of patients. Never miss a major story. Get breaking news and the latest developments from South Africa and beyond as they happen.